Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits

Hypertension Research : Official Journal of the Japanese Society of Hypertension
Toshio ImanishiTakashi Akasaka

Abstract

We investigated the effects of co-administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor and angiotensin II type 1 receptor blocker (ARB) on nitric oxide (NO) bioavailability in genetically hyperlipidemic rabbits with our newly developed NO sensor. A total of 36 myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits equally derived (n=6 per group) were treated with 1) vehicle (control), 2) hydralazine (15 mg/kg/d), 3) the HMG-CoA reductase inhibitor pitavastatin (P: 0.5 mg/kg/d), 4) the ARB valsartan (V: 5 mg/kg/d), and 5) pitavastatin+valsartan (P+V) together without or 6) with N(G)-nitro-L-arginine methyl ester (L-NAME) for 8 weeks. After treatment, acetylcholine (ACh)-induced NO production was measured as a surrogate for endothelium protective function, and vascular peroxynitrite (a product of superoxide and NO) was measured for assessing dysfunctional endothelial NO synthase activity. Plaque area was quantified by histology as well as optical coherence tomography (OCT). Intra-aortic infusion of ACh produced an increase in plasma NO concentration, which was significantly greater with all drug treatments than with the control. P+V increased ACh-induced NO by 4.1 nmol/L si...Continue Reading

References

Dec 1, 1991·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·W B Kannel
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·P J PaganoM T Quinn
Dec 5, 1998·Free Radical Biology & Medicine·J C ter SteegeW A Buurman
Mar 11, 2000·American Journal of Hypertension·W B Kannel
Nov 18, 2000·Journal of the American College of Cardiology·C CheethamD Green
Mar 30, 2001·The Journal of Biological Chemistry·D StuehrG M Rosen
Feb 19, 2002·Journal of the American College of Cardiology·Ik-Kyung JangGuillermo J Tearney
Sep 25, 2002·Circulation·Hiroshi YabushitaGuillermo J Tearney
Jun 14, 2003·Biochemical and Biophysical Research Communications·Seiichi MochizukiKiyoshi Yoshida
Oct 22, 2003·Circulation·Kathy K Griendling, Garret A FitzGerald
Mar 6, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Seinosuke Kawashima, Mitsuhiro Yokoyama
Nov 16, 2004·The American Journal of Medicine·Ethan M BalkJoseph Lau
Jun 29, 2005·Circulation·Peter Libby, Pierre Theroux
Jul 30, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yoji NeishiMasami Goto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.